Proteome-scale comparative and subtractive genomics reveals conserved, pathogen-specific druggable targets in Pasteurella multocida

Khan, Hizbullah, Ibrahim, Uzaima, Akbar, Iqra, Liu, Bin, Malik, Abdul, Ola, Mohammad Shamsul, Ali, Muhammad Fawad, Ouyang, Ping, Xu, Guangxian, Eshboev, Farkhod, Khan, Asifullah, Huang, Kaisong
BMC Genomics · Springer Nature · 2026-11-20 · DOI: 10.1186/s12864-026-13581-2

Abstract

Haemorrhagic septicaemia caused by Pasteurella multocida serotype B:2 is a rapidly fatal disease of buffalo and remains a major constraint to livestock productivity in endemic regions of Asia. Current control strategies are limited by incomplete vaccine protection and rising antimicrobial resistance, highlighting the need for novel, pathogen-specific therapeutic targets. In this study, we applied an integrated comparative proteomics and subtractive genomics framework to systematically identify conserved, host-non-homologous, and druggable protein targets in P. multocida B:2. A total of 19,412 proteins from nine South Asian P. multocida serotype B:2 strains were analysed through ortholog clustering, host non-homology filtering, essentiality screening, functional annotation, and metabolic prioritisation. This workflow yielded 1,024 host non-homologous proteins and 488 essential proteins, from which five candidate targets were prioritised. These include sialic acid TRAP transporter substrate-binding protein, glycosyltransferase family 2 protein, zinc transporter binding subunit ZevA, flippase, and CidB/LrgB family autolysis modulator. These proteins are associated with key bacterial processes such as nutrient uptake, cell-envelope biosynthesis, zinc homeostasis, membrane lipid transport, and autolysis regulation. Structural modelling, druggability assessment, pharmacophore screening, molecular docking, ADME profiling, and 200-ns molecular dynamics simulations further supported the ligandability and stability of these targets. Among them, glycosyltransferase family 2 protein and flippase showed the most consistent ligand-bound stability across all structural and dynamic analyses. Overall, this study provides a systematic proteome-wide prioritisation of conserved, host-non-homologous druggable targets in P. multocida B:2 and highlights cell-envelope biosynthesis and membrane-associated transport as promising intervention targets for downstream experimental validation and for future anti-haemorrhagic septicaemia therapeutic development. Clinical trial number: Not applicable. Graphical abstract A workflow identifies glycosyltransferase family 2 protein and flippase as two candidate targets in Pasteurella multocida. It starts with 19,412 proteins from nine strains, compares them with the buffalo host reference, and applies subtractive proteomics, subtractive genomics, and prioritisation. Virtual screening and molecular docking are followed by molecular dynamics simulations and analysis.

Read at publisher →

Similar articles